Myopic Shift After the Administration of Omidenepag Isopropyl in Patients with Normal-Tension Glaucoma

Abstract

Purpose: To evaluate myopic shift after the administration of omidenepag isopropyl (OMDI) in patients with normal-tension glaucoma (NTG). Methods: In this retrospective observational study, we enrolled 105 patients (105 eyes) with NTG who had received initial doses of OMDI between December 2018 and October 2022. We recorded the data on subjective refraction (diopters, D) at baseline and at the first visit after administration. We investigated and followed-up patients with myopic shift ?0.75?D from the baseline value. The main outcome measures were refractive changes from baseline to the first visit after administration. Results: This study included 105 patients (52 men and 53 women). The mean refractions at baseline and at the first visit after administration were ?3.87 ? 3.77 and ?3.99 ? 3.79?D, respectively (p < 0.01). Three patients (2.9%) developed myopia ??0.75?D. Among these three patients, OMDI administration was continued in two, and their refraction value returned to <?0.75?D of the baseline value; the medication of the other patient was changed because of blurred vision, and the refraction returned to <?0.75?D of baseline after the change in medication. Conclusions: After administration of OMDI, 2.9% of the patients developed myopic shift ?0.75?D. This myopic shift was transient, as refraction returned to <?0.75?D of baseline after follow-up or medication changes.

Keywords

• myopic shift
• normal-tension glaucoma
• omidenepag isopropyl
• refractive change